Comments on \How Acquisitions A ect Firm Behavior and Performance"

Nathan E. Wilson

Federal Trade Commission Bureau of Economics nwilson@ftc.gov

November 2018

The views expressed are those of the speaker. They do not necessarily represent those of the Federal Trade Commission or any of its Commissioners.

1 1 E

Dialysis Market Trends




Prevalence of ESRD in US expanding rapidly. Patients *now* treated predominantly in for-pro t facilities.

N. E. Wilson (FTC)

Comments on Eliason et al.

Dialysis Market Trends



Rise of for-pro ts due due to acquisitions by large chains as well as faster entry

N. E. Wilson (FTC)

Comments on Eliason et al.

Quick review:

▲御▶ ▲理▶ ▲理≯

э

Quick review:

Paper investigates implications of for-pro t chain dominance using acquisitions of independent clinics

御 と く ヨ と く ヨ と

Quick review:

- Paper investigates implications of for-pro t chain dominance using acquisitions of independent clinics
- Uses extremely rich data on both facilities and patients to establish plausibly causal e ects *and* mechanisms

Quick review:

- Paper investigates implications of for-pro t chain dominance using acquisitions of independent clinics
- Uses extremely rich data on both facilities and patients to establish plausibly causal e ects *and* mechanisms
- Econometric techniques are straightforward examples of treatment e ects estimation

伺 ト イ ヨ ト イ ヨ ト

Quick review:

- Paper investigates implications of for-pro t chain dominance using acquisitions of independent clinics
- Uses extremely rich data on both facilities and patients to establish plausibly causal e ects *and* mechanisms
- Econometric techniques are straightforward examples of treatment e ects estimation
- Patient level evidence shows that acquisitions tend to lead to worse health outcomes for patients
- Facility level evidence points to reduced expenditures on high end inputs and increased doses of highly reimbursed pharmaceuticals

伺 と く ヨ と く ヨ と

N. E. Wilson (FTC) Comments on Eliason et al.

ヘロン ヘロン ヘビン ヘビン

æ

But a couple of modest things to consider:

個 と く ヨ と く ヨ と 。

э

But a couple of modest things to consider:

1. External validity: Most independent acquisitions by *shrinking* minor chains

同下 イヨト イヨト

1 1 E

But a couple of modest things to consider:

- 1. External validity: Most independent acquisitions by *shrinking* minor chains
- 2. Competition: Paper nds that competition plays no role in post-acquisition changes
 - Perhaps explore sensitivity of those conclusions focusing on less heterogeneous sample

But a couple of modest things to consider:

- 1. External validity: Most independent acquisitions by *shrinking* minor chains
- 2. Competition: Paper nds that competition plays no role in post-acquisition changes
 - Perhaps explore sensitivity of those conclusions focusing on less heterogeneous sample
 - How coincident were individual transactions with other market structure changes?

伺 と く ヨ と く ヨ と

1 1 E

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

Compensation incentives certainly encourage heavy dosing, shirking heavy

æ

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

э

Compensation incentives certainly encourage heavy

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

- Compensation incentives certainly encourage heavy dosing, shirking on quality investments
- But why do these only impact for-pro t chains?
- In hospital markets, lots of evidence that non-prot systems leverage market power

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

- Compensation incentives certainly encourage heavy dosing, shirking on quality investments
- But why do these only impact for-pro t chains?
- In hospital markets, lots of evidence that non-prot systems leverage market power
 - Non-pro t hospital mergers lead to higher prices

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

- Compensation incentives certainly encourage heavy dosing, shirking on quality investments
- But why do these only impact for-pro t chains?
- In hospital markets, lots of evidence that non-prot systems leverage market power
 - Non-pro t hospital mergers lead to higher prices
 - Notorious monopolized non-pro t

Why does

æ

Why does for-pro t (or chain) ownership matter so much in dialysis markets?

- Compensation incentives certainly encourage heavy dosing, shirking on quality investments
- But why do these only impact for-pro t chains?
- In hospital markets, lots of evidence that non-prot systems leverage market power
 - Non-pro t hospital mergers lead to higher prices
 - Notorious monopolized markets are dominated by non-pro t systems
 - Non-pro t market power not correlated with increased spending on charity care
- Whaton + pono-for(o) Ttj / di er EMC / P <</ MCID 4 >> BDC 0.2 ET / Figure